CN104619338A - 稳定化的gp120 - Google Patents

稳定化的gp120 Download PDF

Info

Publication number
CN104619338A
CN104619338A CN201380032027.2A CN201380032027A CN104619338A CN 104619338 A CN104619338 A CN 104619338A CN 201380032027 A CN201380032027 A CN 201380032027A CN 104619338 A CN104619338 A CN 104619338A
Authority
CN
China
Prior art keywords
polypeptide
hiv
isolated polypeptide
seq
immunogenic fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380032027.2A
Other languages
English (en)
Chinese (zh)
Inventor
A·卡尔菲
A·德伊
A·卡萨
I·斯里瓦斯塔瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN104619338A publication Critical patent/CN104619338A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380032027.2A 2012-06-18 2013-06-17 稳定化的gp120 Pending CN104619338A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661050P 2012-06-18 2012-06-18
US61/661,050 2012-06-18
PCT/EP2013/062553 WO2013189901A1 (en) 2012-06-18 2013-06-17 Stabilized gp120

Publications (1)

Publication Number Publication Date
CN104619338A true CN104619338A (zh) 2015-05-13

Family

ID=48628698

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380032027.2A Pending CN104619338A (zh) 2012-06-18 2013-06-17 稳定化的gp120

Country Status (14)

Country Link
US (1) US20150183835A1 (enExample)
EP (1) EP2861249A1 (enExample)
JP (1) JP2015521592A (enExample)
KR (1) KR20150023735A (enExample)
CN (1) CN104619338A (enExample)
AU (1) AU2013279456A1 (enExample)
CA (1) CA2876762A1 (enExample)
IL (1) IL235898A0 (enExample)
IN (1) IN2014KN02740A (enExample)
MX (1) MX2014014682A (enExample)
RU (1) RU2015101081A (enExample)
SG (1) SG11201407995RA (enExample)
WO (1) WO2013189901A1 (enExample)
ZA (1) ZA201408840B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109851664A (zh) * 2017-11-30 2019-06-07 清华大学 一种基于抗体反向表位设计的蛋白质及其在制备抗艾滋病病毒疫苗中的应用
CN116034115A (zh) * 2020-06-10 2023-04-28 四川三叶草生物制药有限公司 疫苗组合物、方法及其用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10400015B2 (en) 2014-09-04 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
RU2745373C2 (ru) * 2014-09-23 2021-03-24 БЁРИНГЕР ИНГЕЛЬХАЙМ ЭНИМАЛ ХЕЛТ ЮЭсЭй ИНК. Рекомбинантные вакцины от fmdv и их применение
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10808011B2 (en) 2016-03-09 2020-10-20 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant HIV-1 envelope proteins and their use
WO2018075989A1 (en) 2016-10-21 2018-04-26 Altor Bioscience Corporation Multimeric il-15-based molecules
US11136356B2 (en) 2017-10-16 2021-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
EP3810755A4 (en) 2018-06-19 2021-12-01 Nantcell, Inc. COMPOSITIONS AND METHODS OF TREATMENT FOR HIV

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011038290A2 (en) * 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786488B1 (fr) * 1998-11-27 2003-04-25 Orstom Mutants de la gp120 et leurs applications biologiques
EP1198468A4 (en) * 1999-06-25 2003-07-30 Progenics Pharm Inc STABILIZED VIRAL ENVELOPE PROTEINS AND THEIR USE
BRPI0815743A2 (pt) * 2007-08-24 2015-02-18 Novartis Ag Proteínas hiv env com modificações no laço v3

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011038290A2 (en) * 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FINZI A ET AL.: "Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions", 《MOL CELL》, vol. 37, no. 5, 12 March 2010 (2010-03-12), pages 656 - 667, XP055084948, DOI: doi:10.1016/j.molcel.2010.02.012 *
PANCERA M ET AL.: "Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility", 《PNAS》, vol. 107, no. 3, 19 January 2010 (2010-01-19), pages 1166 - 1171, XP055084839, DOI: doi:10.1073/pnas.0911004107 *
ZHOU T ET AL.: "Structural definition of a conserved neutralization epitope on HIV-1 gp120", 《NATURE》, vol. 445, no. 7129, 15 February 2007 (2007-02-15), pages 732 - 737, XP002563484, DOI: doi:10.1038/NATURE05580 *
柳树群等: "不同构象状态HIV-1 gp120分子运动特征及构象转换能力研究", 《科学通报》, vol. 52, no. 21, 15 November 2007 (2007-11-15), pages 2494 - 2506 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109851664A (zh) * 2017-11-30 2019-06-07 清华大学 一种基于抗体反向表位设计的蛋白质及其在制备抗艾滋病病毒疫苗中的应用
CN116034115A (zh) * 2020-06-10 2023-04-28 四川三叶草生物制药有限公司 疫苗组合物、方法及其用途

Also Published As

Publication number Publication date
RU2015101081A (ru) 2016-08-10
IL235898A0 (en) 2015-01-29
WO2013189901A1 (en) 2013-12-27
ZA201408840B (en) 2016-08-31
KR20150023735A (ko) 2015-03-05
JP2015521592A (ja) 2015-07-30
US20150183835A1 (en) 2015-07-02
AU2013279456A1 (en) 2014-12-18
MX2014014682A (es) 2015-03-04
SG11201407995RA (en) 2015-01-29
IN2014KN02740A (enExample) 2015-05-08
EP2861249A1 (en) 2015-04-22
CA2876762A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
CN104619338A (zh) 稳定化的gp120
Díaz-Salinas et al. Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike
Pancera et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env
US10849970B2 (en) Antibody evolution immunogens
US20230338507A1 (en) Hiv-1 env fusion peptide immunogens and their use
WO2016037154A1 (en) Recombinant hiv-1 envelope proteins and their use
US20230190910A1 (en) Scaffolded hiv-1 vaccine immunogens
CN106459186A (zh) 针对hiv‑1 v1v2 env区域的广谱中和性单克隆抗体
WO2018204080A1 (en) Compositions and methods related to arenavirus immunogens
Chiang et al. Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy
US11872277B2 (en) Compositions and methods related to ebolavirus vaccines
US20170326229A1 (en) Swarm immunization with 54 envelopes from ch505
Lamb et al. Highly specific inhibition of leukaemia virus membrane fusion by interaction of peptide antagonists with a conserved region of the coiled coil of envelope
Cheng Elicitation of antibody responses against the HIV-1 gp41 Membrane Proximal External Region (MPER)
US20250032605A1 (en) Rationally designed immunogens
Javanmardi Engineering programmable platforms in mammalian cells for the rapid characterization of viral proteins
Kwong et al. Structural biology and the design of effective vaccines for HIV-1 and other viruses
Mishra Structural Basis of Antibody-Mediated Immunity against Crimean-Congo Hemorrhagic Fever Virus Glycoproteins
Zvi NMR studies of an HIV-1 peptide in complex with an anti-gp120 neutralizing antibody: Structure and interactions
JPWO2022035739A5 (enExample)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150513

WD01 Invention patent application deemed withdrawn after publication